Fig. 3From: Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort studyCMR parameters, NT-proBNP and prealbumin before and after tafamidis treatment(A) ECV, (B) LV GLS, (C) LogNT-proBNP, and (D) ECV before and after tafamidis treatmentBack to article page